Vital Signs - Pay for Performance: Where is it Headed?

 


This issue of Vital Signs, released on May 24, 2011, provides a strategic insight on the future of pay for performance scenario in healthcare.

Additionally, a company spotlight is provided for Valor Medical. Valor Medical has developed a cyanoacrylate monomer to treat cerebral aneurysms. Neucrylate™ AN will polymerize from a liquid to a sponge like material when it comes in contact with blood. Reimbursement and regulatory news from the FDA is also provided for week of May 2, 2011.

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

Table of Contents

Vital Signs - Pay for Performance: Where is it Headed?Vital Signs: 23 May 2011This week's issue




Related Research

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 24-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.